Interleukin-2 treatment ameliorates murine lupus diffuse alveolar hemorrhage with improvement in T cell subset imbalance
Abstract Objective This study evaluated the therapeutic efficacy and mechanism of interleukin-2 (IL-2) in a pristane-induced murine model of lupus-associated diffuse alveolar hemorrhage (DAH). Methods C57BL/6J mice received intraperitoneal pristane injection to induce lupus-like DAH. IL-2 was administered at varying doses. Disease severity, histopathological alterations, inflammatory infiltration, cytokine profiles, T cell subsets, and apoptosis were assessed using hematoxylin and eosin staining, immunohistochemistry, flow cytometry, ELISA, and TUNEL assays. Transcriptomic sequencing of lung tissue was performed to identify IL-2 treatment related molecular pathways. Results IL-2 treatment reduced the incidence and severity of DAH in a dose-dependent manner, with the 100,000 U dose achieving the best therapeutic effect. Treated mice exhibited improved weight maintenance, reduced lung weight, enhanced survival, ameliorated histopathological damage in the lungs with decreased pulmonary infiltration of F4/80+ macrophages and lowered levels of TNF-α, IL-6, IL-10, MIP-1, and SDF-1 in bronchoalveolar lavage fluid and peripheral blood. IL-2 treatment also increased CD4+ regulatory T cells, reduced effector T cells, improved the Treg/conventional T cells (Tcon) ratio, and corrected Th1/Th2 imbalance. Pulmonary apoptotic cell accumulation was also reduced. Transcriptomic analysis revealed that the IL-2 therapy corrected widespread gene expression abnormalities, suppressing pathways associated with inflammation, chemotaxis, adhesion, and innate immunity, while downregulating IL-6, TNF, IL-1, and Toll-like receptor signaling. Conclusion IL-2 treatment improved murine lupus-associated DAH by restoring T cell homeostasis, suppressing inflammatory cascades, and regulating apoptosis and transcriptomic networks. These findings underscore the potential of IL-2 as a therapeutic candidate for SLE-related DAH and provide novel mechanistic insights for translation.
Authors
- Hongyu Jie (ORCID: https://orcid.org/0000-0002-6175-4055)
- Yuqing Wang (ORCID: https://orcid.org/0009-0009-5356-4903)
- Shixiong Cao (ORCID: https://orcid.org/0009-0003-4822-0096)
- Yongkun Bai
- Xiaozhen Zhao (ORCID: https://orcid.org/0000-0002-9733-057X)
- Haotian Zhou
- Erwei Sun (ORCID: https://orcid.org/0000-0001-5664-513X)
- Xiaolin Sun
- Chuanhui Xu (ORCID: https://orcid.org/0000-0002-3222-7168)
- Junyi Jiang
- Xingyue Zeng
- Wenjuan Zhang
Institutions
- Nanyang Technological University (SG)
- Peking University (CN)
- Tan Tock Seng Hospital (SG)
- Third Affiliated Hospital of Southern Medical University (CN)
- Peking University People's Hospital (CN)
- Beijing Proteome Research Center (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Arthritis Research & Therapy
- Published
- 2026-09-29
- DOI
- https://doi.org/10.1186/s13075-026-03898-4
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00